Comparative Pharmacology
Head-to-head clinical analysis: PHOSLO GELCAPS versus SEVELAMER HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOSLO GELCAPS versus SEVELAMER HYDROCHLORIDE.
PHOSLO GELCAPS vs SEVELAMER HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium acetate binds dietary phosphate in the gastrointestinal tract, forming insoluble calcium phosphate complexes that are excreted in feces, thereby reducing serum phosphate levels.
Sevelamer hydrochloride is a phosphate-binding polymer that binds dietary phosphate in the gastrointestinal tract, preventing its absorption and thereby reducing serum phosphate levels.
Oral: One to two capsules (668-1336 mg calcium acetate) three times daily with meals, titrated to maintain serum phosphate between 3.5-5.5 mg/dL, maximum 4 capsules per meal.
Initial dose: 800-1600 mg orally three times daily with meals. Titrate by 800 mg per meal at 2-week intervals based on serum phosphorus levels. Maintenance: typically 2.4-4.8 g/day divided with meals.
None Documented
None Documented
Not applicable; calcium is a physiologic ion with dynamic regulation; steady-state serum calcium is maintained by homeostatic mechanisms. In overdose, serum calcium half-life is approximately 3-4 hours.
Not applicable; sevelamer is not absorbed. The polymer acts locally in the gastrointestinal tract and does not have a measurable plasma half-life.
Primarily fecal as unabsorbed calcium; renal excretion accounts for <1% of absorbed dose proportional to glomerular filtration rate.
Sevelamer hydrochloride is not absorbed systemically; it is eliminated entirely in the feces as the unchanged polymer. No renal or biliary elimination occurs.
Category C
Category A/B
Phosphate Binder
Phosphate Binder